PARTNER WITH US
The Institute for Biomedical Sciences has more than 50 research collaborators in the United States and globally.
Becoming a National Leader in Advancing Human Health
We’re developing innovative approaches to prevent, diagnose and treat important human diseases. Our institute’s research strengths include:
- Life-threatening Infectious Diseases (COVID-19, STDs, Ebola, Flu, RSV, Measles, Pneumonia)
- Inflammatory Diseases (IBD, otitis media, autoimmune)
- Therapeutics (Novel COVID-19 antiviral drugs)
- Vaccines (Universal vaccines for coronavirus, flu, STDs)
- Microbiome
- Translational Immunology & Immunotherapy
- Cancer
- Cardiovascular & Metabolic Disorders
Working Together to Improve Human Health
Our researchers are developing new vaccines, diagnostics and therapeutics to tackle some of the world’s biggest health issues. To bring these biomedical inventions to the market, they’d like to work with pharmaceutical and biotech companies, foundations, industry sponsors and donors who want to improve the health of people worldwide. Learn more about our patents and inventions.
Research Collaboration
A productive and well-established formal relationship among individuals or institutions is important for initiating successful research collaboration. The Institute for Biomedical Sciences has relationships with organizations around the world. Using well-defined, agreed upon division of responsibilities among the participants, the institute executes collaborative projects that increase the chances of success.
- Centers for Disease Control & Prevention
- Cornell University
- Emory University
- Georgia Institute of Technology
- Harvard University
- Mercer University
- Icahn School of Medicine at Mount
- University of Alabama at Birmingham
- University of Chicago
- University of Colorado
- University of Iowa
- University of Massachusetts
- University of Maryland
- University of Michigan
- Washington University in St Louis
- Yale University
- Animal and Plant Quarantine Agency, South Korea
- Chinese University of Hong Kong, Hong Kong, China
- DanKook University, South Korea
- Fudan University, China
- Karolinska Institutet, Stockholm, Sweden
- KonKuk University, South Korea
- Kumamoto University, Japan
- La Sapienza, Rome, Italy
- Medical Research Council, United Kingdom
- Nanjing University, China
- National Institute of Infectious Diseases, Japan
- Örebro University Hospital, Örebro, Sweden
- Paul-Ehrlich Institut, Germany
- Faculte des Sciences et Techniques, Marseille, France
- University of Bern, Switzerland
- Université de Nantes, Faculte de Medecine de Nantes, France
- Université Paul Cézanne, Equipe Biochimie Alimentaire
- Amgen, United States
- Beams Biotech, South Korea
- Korea Ginseng Corp., South Korea
- Polygene AG, Rumlang, Switzerland
- TOBICO Co. Ltd., South Korea
Information for Industry
COLLABORATE ON RESEARCH STUDIES
There’s power in collaboration. We’d like to partner with biotech and pharmaceutical companies on antiviral drug and vaccine development research projects to increase the possibilities of making lasting changes in human health.
FUND PRELIMINARY PILOT STUDIES / SPONSOR RESEARCH
When our researchers pursue preliminary pilot studies, they’re launching projects that could lead to groundbreaking discoveries. These pilot studies need financial support to be successful, and seed funding from companies, foundations or private donors can provide vital resources until researchers can secure grant funding. If intellectual property results from sponsored research, industry sponsors may receive an opportunity to discuss commercialization.
COMMERCIALIZE OUR PATENTS & INVENTIONS
Our institute has been making exciting progress on biomedical patents and inventions that have the potential to improve and save human lives. We’re seeking opportunities to commercialize our patents and inventions and bring them to the market.
Information for Researchers
PARTNER ON RESEARCH STUDIES
Collaborative and multidisciplinary research partnerships can lead to extraordinary scientific breakthroughs. We’d like to partner with other investigators, particularly scientists at Georgia State, on research projects designed to advance human health.
LEARN ABOUT OUR LATEST PROJECTS
Review the institute’s areas of research strengths and some of our featured research publications in the highest ranked scientific journals in the field.
EXPLORE OUR RESEARCH CENTERS
The institute’s four research centers are focused on microbial pathogenesis, translational immunology, antiviral drug development, and inflammation, immunity and infection. Learn more.
Institute Highlights
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.
4 Research centers focused on microbial pathogenesis, translational immunology and inflammation, immunity and infection
“We’re responding to the pressing need for research discoveries that can directly benefit patients by developing new vaccines, diagnostics and therapeutics that can target an array of critical human illnesses.”
Jian-Dong Li, M.D., Ph.D.
Director
University Tech Transfer and Commercialization
Industry Partnerships
Industry Collaboration
Available Technologies
Administrative Team
We’re ready to partner with you. Please contact us to collaborate on research projects, fund preliminary pilot studies designed to advance human health or discuss commercialization opportunities.
Contact for General Questions
LaTina Emerson
Director of Communications
Institute for Biomedical Sciences
Our Address
Parker H. Petit Science Center
100 Piedmont Ave
Atlanta, GA 30303